



## Clinical trial results:

**An open-label proof of concept study to assess the efficacy, safety and pharmacokinetics of LFG316, an anti C5 monoclonal antibody in patients with paroxysmal nocturnal hemoglobinuria (PNH)**

### Summary

EudraCT number	2014-005338-74
Trial protocol	CZ LT
Global end of trial date	24 May 2022

### Results information

Result version number	v2 (current)
This version publication date	24 November 2024
First version publication date	08 June 2023
Version creation reason	

### Trial information

#### Trial identification

Sponsor protocol code	CLFG316X2201
-----------------------	--------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02534909
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Novartis Pharma AG
Sponsor organisation address	Novartis Campus, Basel, Switzerland,
Public contact	Clinical Disclosure Office, Novartis Pharma AG, 41 613241111, novartis.email@novartis.com
Scientific contact	Clinical Disclosure Office, Novartis Pharma AG, 41 613241111, novartis.email@novartis.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

---

Analysis stage	Final
Date of interim/final analysis	24 May 2022
Is this the analysis of the primary completion data?	Yes
Primary completion date	24 May 2022
Global end of trial reached?	Yes
Global end of trial date	24 May 2022
Was the trial ended prematurely?	No

Notes:

---

**General information about the trial**

---

Main objective of the trial:

The purpose of this study was to determine whether LFG316 can induce a hematological response, as measured by reduction in hemolytic activity, in patients with paroxysmal nocturnal hemoglobinuria (PNH).

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	09 September 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

Country: Number of subjects enrolled	Japan: 7
Country: Number of subjects enrolled	Czechia: 2
Country: Number of subjects enrolled	Lithuania: 1
Worldwide total number of subjects	10
EEA total number of subjects	3

Notes:

---

**Subjects enrolled per age group**

---

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	9

From 65 to 84 years	1
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

10 participants were enrolled at 7 sites in 3 countries.

### Pre-assignment

Screening details:

The study had a 60-day screening period to assess eligibility.

### Period 1

Period 1 title	Treatment Period 1 to 3 (up to Week 312)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Arm title	LFG316 then LNP023
-----------	--------------------

Arm description:

Treatment periods 1 to 3: LFG316 20 mg/kg intravenous (i.v.) infusion every 2 weeks. Treatment period 4: LFG316 20 mg/kg intravenous (i.v.) infusion every 2 weeks (Week 1 to 4) + LNP023 200 mg twice per day (b.i.d.) for approximately 20 weeks (Weeks 1 to 20)

Arm type	Experimental
Investigational medicinal product name	LFG316
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Oral lyophilisate, Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

LFG316 20 mg/kg was administered to all patients enrolled in the study:

~ Treatment Periods 1 to 3: LFG316 20 mg/kg as i.v. infusion every 2 weeks

Number of subjects in period 1	LFG316 then LNP023
Started	10
Completed	9
Not completed	1
Consent withdrawn by subject	1

### Period 2

Period 2 title	Treatment Period 4 (20 weeks)
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

## Arms

<b>Arm title</b>	LFG316 then LNP023
------------------	--------------------

Arm description:

Treatment periods 1 to 3: LFG316 20 mg/kg intravenous (i.v.) infusion every 2 weeks. Treatment period 4: LFG316 20 mg/kg intravenous (i.v.) infusion every 2 weeks (Week 1 to 4) + LNP023 200 mg twice per day (b.i.d.) for approximately 20 weeks (Weeks 1 to 20)

Arm type	Experimental
Investigational medicinal product name	LNP023
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

Treatment Period 4: LNP023 200 mg b.i.d. for approximately 20 weeks. Four capsules (each 50 mg) were administered each time study medication was taken.

Investigational medicinal product name	LFG316
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Oral lyophilisate, Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

LFG316 20 mg/kg was administered to all patients enrolled in the study:

~ Treatment Period 4: LFG316 20 mg/kg as i.v. infusion every 2 weeks for 4 weeks (total 2 infusions).

<b>Number of subjects in period 2</b>	LFG316 then LNP023
Started	9
Completed	9

## Baseline characteristics

### Reporting groups

Reporting group title	LFG316 then LNP023
-----------------------	--------------------

Reporting group description:

Treatment periods 1 to 3: LFG316 20 mg/kg intravenous (i.v.) infusion every 2 weeks. Treatment period 4: LFG316 20 mg/kg intravenous (i.v.) infusion every 2 weeks (Week 1 to 4) + LNP023 200 mg twice per day (b.i.d.) for approximately 20 weeks (Weeks 1 to 20)

Reporting group values	LFG316 then LNP023	Total	
Number of subjects	10	10	
Age Categorical			
Units: Participants			
<=18 years	0	0	
Between 18 and 65 years	9	9	
>=65 years	1	1	
Age Continuous			
Units: Years			
arithmetic mean	43.0		
standard deviation	± 11.68	-	
Sex: Female, Male			
Units: Participants			
Female	4	4	
Male	6	6	
Race/Ethnicity, Customized			
Units: Subjects			
Caucasian	3	3	
Asian	7	7	

## End points

### End points reporting groups

Reporting group title	LFG316 then LNP023
Reporting group description:	
Treatment periods 1 to 3: LFG316 20 mg/kg intravenous (i.v.) infusion every 2 weeks. Treatment period 4: LFG316 20 mg/kg intravenous (i.v.) infusion every 2 weeks (Week 1 to 4) + LNP023 200 mg twice per day (b.i.d.) for approximately 20 weeks (Weeks 1 to 20)	
Reporting group title	LFG316 then LNP023
Reporting group description:	
Treatment periods 1 to 3: LFG316 20 mg/kg intravenous (i.v.) infusion every 2 weeks. Treatment period 4: LFG316 20 mg/kg intravenous (i.v.) infusion every 2 weeks (Week 1 to 4) + LNP023 200 mg twice per day (b.i.d.) for approximately 20 weeks (Weeks 1 to 20)	

### Primary: Percentage of participants with Reduction in serum lactate dehydrogenase (LDH) levels within the first 4 weeks of LFG316 treatment as measured by response rate

End point title	Percentage of participants with Reduction in serum lactate dehydrogenase (LDH) levels within the first 4 weeks of LFG316 treatment as measured by response rate <sup>[1]</sup>
End point description:	
The primary efficacy variable for assessing the effect of LFG316 over the first 4 weeks of treatment was response rate where a patient was considered a responder if the percentage reduction from baseline in serum lactate dehydrogenase (LDH) was at least 60% at any time up to and including week 4 for that patient.	
End point type	Primary
End point timeframe:	
Overall (Up to Week 4), Period 1 Day 8, Period 1 Day 15, Period 1 Day 22, Period 1 Day 29	

#### Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to EudraCT system limitations, there must be at least two comparison groups selected for statistical analysis to be entered in the EudraCT system.

End point values	LFG316 then LNP023			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Participants				
Overall (Up to Week 4) Responder	10			
Period 1 Day 8 Responder	6			
Period 1 Day 15 Responder	9			
Period 1 Day 22 Responder	9			
Period 1 Day 29 Responder	9			
Overall (Up to Week 4) Non Responder	0			
Period 1 Day 8 Non Responder	4			
Period 1 Day 15 Non Responder	1			
Period 1 Day 22 Non Responder	1			
Period 1 Day 29 Non Responder	1			

## Statistical analyses

No statistical analyses for this end point

### Primary: Percentage change from baseline in serum lactate dehydrogenase (LDH) levels over the entire treatment period

End point title	Percentage change from baseline in serum lactate dehydrogenase (LDH) levels over the entire treatment period <sup>[2]</sup>
-----------------	---

End point description:

Lactate dehydrogenase (LDH) levels were measured in serum samples and the percentage change from baseline was calculated. For serum LDH, baseline was the average of all pre-dose measurements.

End point type	Primary
----------------	---------

End point timeframe:

Baseline, Period 1 Day 29 (end of Treatment Period 1), Period 2 Day 365 (end of Treatment Period 2), Period 3 Day 1429 (end of Treatment Period 3), Period 4 Day 141 (end of Treatment Period 4)

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to EudraCT system limitations, there must be at least two comparison groups selected for statistical analysis to be entered in the EudraCT system.

End point values	LFG316 then LNP023			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: % change from baseline in serum LDH				
arithmetic mean (standard deviation)				
Period 1 Day 29	-78.35 (± 11.190)			
Period 2 Day 365	-78.56 (± 11.550)			
Period 3 Day 1429	-81.65 (± 8.138)			
Period 4 Day 141	-78.69 (± 9.288)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: LFG316 serum concentration

End point title	LFG316 serum concentration
-----------------	----------------------------

End point description:

The concentration of total LFG316 in serum was determined using Liquid chromatography/mass spectroscopy (LC/MS assay) and summarized using descriptive statistics.

End point type	Secondary
----------------	-----------

End point timeframe:

Period 1 Day 1 (predose (trough), post-dose), Period 2 Day 337 (predose), Period 3 Day 1289 (predose)



<b>End point values</b>	LFG316 then LNP023			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: nanograms per milliliter (µg/mL)				
arithmetic mean (standard deviation)				
Period 1 Day 1 (predose (trough))	182 (± 31.4)			
Period 1 Day 1 (postdose)	538 (± 80.0)			
Period 2 Day 337 (predose)	248 (± 55.9)			
Period 3 Day 1289 (predose)	313 (± 89.2)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Maximum observed serum concentration (Cmax) for LFG316

End point title	Maximum observed serum concentration (Cmax) for LFG316
-----------------	--

End point description:

Venous whole blood samples were collected for activity-based pharmacokinetics characterization of LFG316. Pharmacokinetic parameters were determined using non-compartmental methods based on LFG316 concentrations in serum. Cmax was summarized using descriptive statistics.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-infusion and 2 hours after the end of infusion on Period 1 Day 1.

<b>End point values</b>	LFG316 then LNP023			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: nanograms per milliliter (µg/mL)				
arithmetic mean (standard deviation)	407 (± 69.2)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Time to reach maximum serum concentration (Tmax) for LFG316

End point title	Time to reach maximum serum concentration (Tmax) for LFG316
-----------------	---

End point description:

Venous whole blood samples were collected for activity-based pharmacokinetics characterization of LFG316. Pharmacokinetic parameters were determined using non-compartmental methods based on LFG316 concentrations in serum. Tmax was summarized using descriptive statistics. Actual sampling times were used for the calculation of PK parameters.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-infusion and 2 hours after the end of infusion on Period 1 Day 1.

<b>End point values</b>	LFG316 then LNP023			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: hour (h)				
median (full range (min-max))	2.56 (2.05 to 3.10)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Area under the concentration-time curve (AUC) from time zero to the last measurable serum concentration sampling time (0-tlast) for LFG316

End point title	Area under the concentration-time curve (AUC) from time zero to the last measurable serum concentration sampling time (0-tlast) for LFG316
-----------------	--

End point description:

Venous whole blood samples were collected for activity-based pharmacokinetics characterization of LFG316. Pharmacokinetic parameters were determined using non-compartmental methods based on LFG316 concentrations in serum. AUC (0-tlast) was summarized using descriptive statistics.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-infusion and 2 hours after the end of infusion on Period 1 Day 1.

<b>End point values</b>	LFG316 then LNP023			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: hour*microgram/milliliter (h*µg/mL)				
arithmetic mean (standard deviation)	73700 (± 12600)			

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

AEs were collected from the 1st LFG316 dose until 4 wks after the 1st dose for pts in Period 4 or up to 8 wks for pts ending their participation after Period 3. In Period 4, AEs were coll. from the 1st LNP023 dose until 30 days after the 1st dose of tx.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	25.0
--------------------	------

### Reporting groups

Reporting group title	LFG316 Periods 1 to 3
-----------------------	-----------------------

Reporting group description:

LFG316 Periods 1 to 3

Reporting group title	LFG316 + LNP023 Period 4
-----------------------	--------------------------

Reporting group description:

LFG316 + LNP023 Period 4

Serious adverse events	LFG316 Periods 1 to 3	LFG316 + LNP023 Period 4	
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 10 (30.00%)	0 / 9 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Renal and urinary disorders			
Renal impairment			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Bacteraemia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocolitis viral			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza			

subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasopharyngitis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infection			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	LFG316 Periods 1 to 3	LFG316 + LNP023 Period 4	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	10 / 10 (100.00%)	6 / 9 (66.67%)	
Vascular disorders			
Hypertension			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
Embolism			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	7	0	
Oedema peripheral			
subjects affected / exposed	2 / 10 (20.00%)	0 / 9 (0.00%)	
occurrences (all)	2	0	
Non-cardiac chest pain			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
Immune system disorders			

Immunisation reaction subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 9 (0.00%) 0	
Reproductive system and breast disorders Benign prostatic hyperplasia subjects affected / exposed occurrences (all)  Erectile dysfunction subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1  1 / 10 (10.00%) 1	0 / 9 (0.00%) 0  0 / 9 (0.00%) 0	
Respiratory, thoracic and mediastinal disorders Epistaxis subjects affected / exposed occurrences (all)  Oropharyngeal pain subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 2  1 / 10 (10.00%) 1	0 / 9 (0.00%) 0  0 / 9 (0.00%) 0	
Psychiatric disorders Insomnia subjects affected / exposed occurrences (all)  Sleep disorder subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1  1 / 10 (10.00%) 1	0 / 9 (0.00%) 0  0 / 9 (0.00%) 0	
Investigations Blood creatine phosphokinase increased subjects affected / exposed occurrences (all)  International normalised ratio decreased subjects affected / exposed occurrences (all)  International normalised ratio increased subjects affected / exposed occurrences (all)  Platelet count increased	2 / 10 (20.00%) 3  1 / 10 (10.00%) 1  1 / 10 (10.00%) 1	0 / 9 (0.00%) 0  0 / 9 (0.00%) 0  0 / 9 (0.00%) 0	

subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
Pulmonary function test decreased			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
Injury, poisoning and procedural complications			
Arthropod bite			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
Contusion			
subjects affected / exposed	2 / 10 (20.00%)	0 / 9 (0.00%)	
occurrences (all)	2	0	
Meniscus injury			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
Peripheral nerve injury			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
Shunt stenosis			
subjects affected / exposed	1 / 10 (10.00%)	1 / 9 (11.11%)	
occurrences (all)	7	2	
Thermal burn			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
Tooth fracture			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
Wound			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
Congenital, familial and genetic disorders			
Brugada syndrome			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
Cardiac disorders			

Sinus bradycardia subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 4	0 / 9 (0.00%) 0	
Atrioventricular block first degree subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 3	0 / 9 (0.00%) 0	
Nervous system disorders			
Headache subjects affected / exposed occurrences (all)	5 / 10 (50.00%) 8	1 / 9 (11.11%) 2	
Migraine subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 4	0 / 9 (0.00%) 0	
Migraine with aura subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 9 (0.00%) 0	
Blood and lymphatic system disorders			
Thrombocytosis subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 9 (0.00%) 0	
Neutropenia subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 2	0 / 9 (0.00%) 0	
Leukopenia subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 9 (0.00%) 0	
Haemolysis subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 9 (0.00%) 0	
Anaemia subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 8	0 / 9 (0.00%) 0	
Ear and labyrinth disorders			
Vertigo subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 9 (0.00%) 0	
Eye disorders			

Conjunctival haemorrhage subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 3	0 / 9 (0.00%) 0	
Gastrointestinal disorders			
Abdominal pain subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 9 (0.00%) 0	
Abdominal pain upper subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 2	0 / 9 (0.00%) 0	
Diarrhoea subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 2	0 / 9 (0.00%) 0	
Dental caries subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 2	0 / 9 (0.00%) 0	
Colitis subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 9 (0.00%) 0	
Toothache subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 2	0 / 9 (0.00%) 0	
Stomatitis subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 2	0 / 9 (0.00%) 0	
Nausea subjects affected / exposed occurrences (all)	3 / 10 (30.00%) 3	0 / 9 (0.00%) 0	
Gastritis erosive subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 9 (0.00%) 0	
Gastritis subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 9 (0.00%) 0	
Enterocolitis			



subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
Enteritis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
Duodenal ulcer			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
Mouth haemorrhage			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
Skin and subcutaneous tissue disorders			
Dermatitis			
subjects affected / exposed	2 / 10 (20.00%)	0 / 9 (0.00%)	
occurrences (all)	2	0	
Dry skin			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
Haemorrhage subcutaneous			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
Pruritus			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	2	0	
Rash			
subjects affected / exposed	2 / 10 (20.00%)	0 / 9 (0.00%)	
occurrences (all)	3	0	
Rash maculo-papular			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
Seborrhoeic dermatitis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	2	0	
Renal and urinary disorders			
Calculus urinary			

subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	2	0	
Haematuria			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	6	0	
Proteinuria			
subjects affected / exposed	1 / 10 (10.00%)	1 / 9 (11.11%)	
occurrences (all)	7	2	
Renal colic			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	2	
Renal cyst			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
Nephrolithiasis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	2 / 10 (20.00%)	0 / 9 (0.00%)	
occurrences (all)	4	0	
Back pain			
subjects affected / exposed	3 / 10 (30.00%)	0 / 9 (0.00%)	
occurrences (all)	3	0	
Osteochondrosis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
Pain in extremity			
subjects affected / exposed	1 / 10 (10.00%)	1 / 9 (11.11%)	
occurrences (all)	1	2	
Infections and infestations			
Gastroenteritis			
subjects affected / exposed	3 / 10 (30.00%)	0 / 9 (0.00%)	
occurrences (all)	3	0	
Helicobacter infection			

subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
Herpes simplex			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	9	0	
Herpes zoster			
subjects affected / exposed	3 / 10 (30.00%)	0 / 9 (0.00%)	
occurrences (all)	4	0	
Lyme disease			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
Nasopharyngitis			
subjects affected / exposed	8 / 10 (80.00%)	0 / 9 (0.00%)	
occurrences (all)	29	0	
Paronychia			
subjects affected / exposed	2 / 10 (20.00%)	0 / 9 (0.00%)	
occurrences (all)	3	0	
Pharyngitis			
subjects affected / exposed	2 / 10 (20.00%)	0 / 9 (0.00%)	
occurrences (all)	2	0	
Respiratory tract infection			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
Respiratory tract infection viral			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
Upper respiratory tract infection			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
Cystitis			
subjects affected / exposed	4 / 10 (40.00%)	0 / 9 (0.00%)	
occurrences (all)	4	0	
Cellulitis			
subjects affected / exposed	1 / 10 (10.00%)	1 / 9 (11.11%)	
occurrences (all)	1	2	
Metabolism and nutrition disorders			

Dehydration			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
Hyperferritinaemia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
Hypertriglyceridaemia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	5	0	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
08 May 2015	<p>The main purpose of this amendment was to address a Health Authority request to amend inclusion criterion #7. The amendment specified that treatment with LFG316 may only be initiated at the earliest 2 weeks after meningococcal vaccination. The previous wording allowed the administration of study drug immediately after vaccination, provided that prophylactic antibiotics were used for at least 2 weeks.</p> <p>Other changes included clarifications and changes to wording, and minor corrections and corrections for typographical errors.</p>
23 June 2015	<p>The main purpose of this amendment was to address a request from the Health Authority of the Czech Republic to lower the maximum age of patients eligible for participation in this clinical study from 75 to 65 years of age in the Czech Republic.</p> <p>A requirement for close medical supervision at the study site during the infusion time of LFG316 and up to 2 hours after the end of the infusion during Treatment Period 1 was included.</p>
30 June 2015	<p>The main purpose of this amendment was to address clarification requests from the Health Authority of Japan with regards to vaccination requirements, safety follow-up, and safety measures in case of specific adverse events (e.g., infusion reactions).</p>
21 October 2015	<p>The main purpose of this amendment was to extend the screening period from 28 to 60 days to enable and comply with local recommendations for vaccination whenever available and if deemed necessary at investigator's discretion.</p> <p>Inclusion Criterion #2 was modified by removing the time limit from the moment of diagnosis of PNH (i.e., 6 months). Based on the chronicity of the disease, the certainty of the diagnosis, and investigators feedback, the 6 months were not deemed necessary to define eligibility of the patients.</p> <p>Clarifications on Exclusion Criterion #09 and #10 were added.</p> <p>Minor corrections and clarifications were made.</p>
15 June 2016	<p>The main purpose of this amendment was to ensure a seamless continuation of treatment in LFG316-responsive patients already enrolled in the study, and to continue to assess long term safety, efficacy, pharmacokinetic and pharmacodynamic data beyond 48 weeks.</p> <p>The study design was updated with the addition of extension period 3.</p> <p>Additional changes were made to reduce patients' burden and to clarify exclusion criteria.</p>

21 September 2017	<p>The main purpose of this amendment was to allow recruitment of up to approximately five additional PNH patients who were refractory to eculizumab therapy due to a genetic variant leading to amino acid exchange (Arg885His) in the C5 protein, due to a lack of effective treatment options in this subpopulation of PNH patients.</p> <p>The upper age limit was removed to allow older variant patients to participate in the study. To date, patients up to 82 years old were safely treated with LFG316 and considering lack of any treatment options it is deemed justified to allow treatment of older PNH patients.</p> <p>As there were no safety concerns in study CLFG316B2102 in healthy volunteers infused over 30 and 60 minutes, it was considered appropriate to decrease the required infusion time in Periods 2 and 3 from approximately 2 hours to a minimum of 40 minutes.</p>
05 March 2019	<p>The main purpose of this amendment was to stop the recruitment into the trial, and to extend the study treatment for currently enrolled patients beyond the 3rd year in period 3.</p> <p>The assessment schedule reflects a reduced number of study visits and assessments during the extended period 3 with focus on safety assessments as the reason for this amendment is to secure extended LFG316 treatment access for patients currently enrolled in the trial.</p> <p>In addition, updated guidance about consent, withdrawal and early study termination is provided.</p>
15 December 2020	<p>The main purpose of this amendment was to convert ongoing study patients from LFG316 to LNP023, a potent, selective and reversible low molecular weight Factor B (FB) inhibitor for oral administration and allow them to be considered for participation in an open label extension study with LNP023 (CLNP023C12001B).</p> <p>Treatment period 4 was implemented to convert patients with PNH receiving i.v. LFG316 to oral LNP023.</p> <p>As per strategic decision, further development of LFG316 was terminated in favor of LNP023, Novartis offered patients enrolled in study CLFG316X2201 a conversion from LFG316 to LNP023, aiming to provide uninterrupted treatment for these PNH patients. With a protocol amendment, study Period 4 was implemented to allow patients to first convert from LFG316 to LNP023 therapy and then to join the separate LNP023 roll-over extension study CLNP023C12001B.</p>

Notes:

## Interruptions (globally)

Were there any global interruptions to the trial? No

## Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

LFG316 development was terminated in favor of LNP023. CLFG316X2201 patients were offered conversion from LFG316 to LNP023 for uninterrupted treatment.

Notes: